Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

GlaxoSmithKline and Tolerx announced March 11 that their humanized anti-CD3 monoclonal antibody, otelixizumab failed to meet the primary endpoint in the Phase III DEFEND-1 trial for type 1 diabetes, and they were halting recruitment and dosing in another Phase III trial, DEFEND-2, while they review the DEFEND-1 results.

You may also be interested in...



GSK Announces Share Buyback Program As Pretax Profits Fall By 52% In 2010

GlaxoSmithKline plans to divest non-core OTC brands this year as CEO describes 2010 as a challenging year.

GSK Signs Deal For Tolerx Anti-CD3 Antibody For Type 1 Diabetes

Tolerx plans to file BLA for humanized anti-CD3 monoclonal antibody in type 1 diabetes in late 2010, CEO tells “The Pink Sheet” DAILY.

Lilly Sweet On MacroGenics’ Novel Diabetes Drug Teplizumab

Anti-CD3 monoclonal antibody is now in a pivotal Phase II/III clinical trial for treating underlying disease in type 1 diabetes, Lilly tells “The Pink Sheet” DAILY.

Topics

UsernamePublicRestriction

Register

PS004701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel